Artificial intelligence; AI devices in health care; qualified end-user; deployer; quality assurance program; State Department of Health; effective date.
HB1915 creates a new regulatory framework in Title 63 for the use of artificial intelligence and machine learning-enabled medical devices in Oklahoma health care settings. The bill defines key terms such as “AI device,” “deployer,” and “qualified end-user,” and limits use of these devices to qualified end-users who are licensed physicians with the training to independently perform the relevant medical function and evaluate the device’s output.
The bill requires AI devices used in patient care to comply with applicable FDA and other federal regulations, and it directs deployers such as hospitals, physician practices, and other health care facilities to implement a Quality Assurance Program. Before patient care decisions are made, device-generated data must be reviewed and validated by a qualified end-user, who retains authority to amend or overrule AI outputs based on professional judgment. Deployers must also conduct performance evaluations, risk assessments, and continuous monitoring, maintain documentation and override summaries, keep an updated inventory of devices, and document use cases and training procedures.
HB1915 also establishes an AI governance group with qualified end-user representation and requires deployers to comply with state and federal privacy, security, and nondiscrimination rules. The Oklahoma State Department of Health is given enforcement authority and rulemaking power, including the ability to set penalties for noncompliance. The act would take effect November 1, 2025.
The available context shows no recorded committee transcript or vote history, so there is little direct evidence of legislative debate or opposition. Based on the bill’s structure, the measure appears aimed at cautious adoption of AI in medicine, emphasizing physician oversight, documentation, and patient safety rather than broad deployment. Any likely contention would center on compliance burdens for health care providers, the cost of monitoring and reporting requirements, and the extent of state oversight over emerging medical AI tools.
The bill would add new provisions to Title 63 of the Oklahoma Statutes governing AI and machine learning-enabled medical devices in health care. It would impose operational, documentation, governance, and oversight requirements on hospitals, physician practices, and other health care facilities that deploy such devices, while authorizing the State Department of Health to enforce the act and adopt rules and penalties. It also reinforces that AI tools in patient care remain subordinate to licensed physician judgment and must be used in compliance with federal medical-device rules.
No committee discussion or vote record is available in the provided context, so there is no documented floor or committee sentiment to summarize. The bill’s text suggests a generally cautious, patient-safety-oriented approach to AI in health care, with an emphasis on oversight, validation, and accountability rather than promotion of AI adoption. The absence of recorded opposition or support makes the overall sentiment difficult to gauge beyond the bill’s protective framing.
The main potential points of contention are the administrative and compliance burdens placed on health care deployers, including quality assurance programs, continuous monitoring, documentation of overrides, and participation in assessment registries when feasible. Providers may also question the practical feasibility of requiring exclusive use by a qualified end-user and the scope of Department of Health enforcement and rulemaking authority. Supporters would likely emphasize patient safety, physician autonomy, and the need for oversight of rapidly evolving medical AI systems.